AIMT News and Press, Aimmune Therapeutics Inc. From 02/28/19

Aimmune Therapeutics (NASDAQ: AIMT ): Q4 GAAP EPS of -$0.95 misses by $0.04 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...

FDA decision on AR101 BLA filing acceptance expected by end of March Submission of AR101 marketing application in Europe on track for mid-2019 Initiation of AR201 phase 2 trial in egg allergy on track for mid-2019 Company began 2019 with approximately $340 million in cas...

ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...

— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE — — AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any D...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ...

Aimmune ( AIMT ) suffered a setback and through no fault of its own. It was notified by the FDA that its Biologics Licensing Application ((BLA)) would not be reviewed because of the government shutdown. The stock fell about 5% on Monday after the release of the news, and then slightly ag...

— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today anno...